PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity

By sjmartinez • November 27, 2024

Varuzhanyan G, Chen CC, Freeland J, He T, Tran W, Song K, Wang L, Cheng D, Xu S, Dibernardo GA, Esedebe FN, Bhatia V, Han M, Abt ER, Park JW, Memarzadeh S, Shackelford DB, Lee JK, Graeber TG, Shirihai OS, Witte ON. PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity. Proc Natl Acad Sci U S A. 2024 Dec 3;121(49):e2416882121. doi: 10.1073/pnas.2416882121. Epub 2024 Nov 26. PMID: 39589879.

Tags: ASCL1, Endocrinology, Hematology/Oncology, Lung cancer, Oxidative phosphorylation, PGC-1a, prostate cancer, Publications, Pulmonary, Critical Care & Sleep Medicine

Closing the Distance: A Qualitative Study to Identify Equitable Innovations for Rural Thyroid Cancer Treatment

Huston-Paterson HH, Mao YV, Hughes EG, Bobanga I, Wu JX, Yeh MW. Closing the Distance: A Qualitative Study to Identify Equitable Innovations for Rural Thyroid[...]

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

Perry AS, Hadad N, Chatterjee E, Jimenez-Ramos M, Farber-Eger E, Roshani R, Stolze LK, Betti MJ, Zhao S, Huang S, Martens L, Kendall TJ, Thone[...]

Evaluation of dimethandrolone undecanoate in non-human primates as a candidate for long-acting injectable male contraceptive

Bunin DI, Kim K, Parman T, Gahagen J, Zelinski MB, Adevai T, Wang C, Tang L, Iyer L, Endsley A, Blithe DL, Lee MS. Evaluation[...]